RxDoctor Payments Data

Kun Xiang

Cardiovascular Disease · Ocala, FLNPI 1144451873

Payments from drug & device makers

$125,204in general payments, 2019–2025

Across 484 payments — averaging $258.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$49K
  • Biotronik Inc.$27K
  • Medtronic$22K
  • Abbott$18K
  • Boston Scientific$4K
  • Altathera Pharmaceuticals LLC$3K
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$19,57521%
  • Speaking & faculty fees$5001%
  • Travel & lodging$55,58059%
  • Food & beverage$18,43220%
  • Education$1850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$125,204 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$264,826
Medicare patients
993
Services billed
3,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban193$196,516
EntrestoSacubitril/Valsartan42$38,091
MultaqDronedarone Hcl12$15,844
XareltoRivaroxaban12$10,942
Metoprolol Succinate156$2,233
Midodrine Hcl18$1,717
Amiodarone Hcl92$1,286
Atorvastatin Calcium43$425
Losartan Potassium61$396
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$381
Flecainide Acetate17$379
SotalolSotalol Hcl14$345
Lisinopril50$300
Bumetanide15$260
Carvedilol42$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$20$38,09142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →